Vaccine effects on COVID-19 infection with bivalent boosting by age group

Elsevier

Available online 27 December 2023, 101039

Drug Resistance UpdatesAuthor links open overlay panelABSTRACT

This paper examines time-series vaccine effectiveness on COVID-19 infection with/without a bivalent booster dose by 6 age groups such as 18-29, 30-49, 50-64, 65-79, 80+, and all_ages respectively. CDC’s COVID data on rates of COVID-19 cases and deaths by updated (bivalent) booster status was used in this study. This result concludes that there is no difference between vaccines with or without a bivalent booster dose for preventing COVID-19 infection in 6 age groups 18-29, 30-49, 50-64, 65-79, 80+, and all_ages. Vaccination is effective in two age groups of 65-79 and 80+ for preventing COVID-19 infection. However, vaccine effectiveness against COVID-19 infection has not been confirmed in the 18-29 and 30-49 age groups.

Section snippetsFunding

This research has no fund.

Declaration of Competing Interest

The author has no conflict of interest.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References (9)

There are more references available in the full text version of this article.

View full text

© 2023 Elsevier Ltd. All rights reserved.

Comments (0)

No login
gif